ArticleCureus2026
Predictive Value of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio in Preeclampsia and Placenta Accreta Spectrum: A Prospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCertain placentation disorders, such as preeclampsia and placenta accreta spectrum (PAS), are prevalent causes of maternal and fetal morbidity. Angiogenic biomarkers, including soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and the sFlt-1/PlGF ratio, are increasingly used in the evaluation of preeclampsia; however, their relevance in PAS remains unclear.
objectiveTo evaluate the diagnostic performance of sFlt-1, PlGF, and the sFlt-1/PlGF ratio for preeclampsia and explore their potential diagnostic utility in PAS. METHODOLOGY: This prospective observational study was conducted at a tertiary care hospital in North India from June 2024 to June 2025. A total of 200 antenatal women at 20-37 weeks of gestation were recruited and divided into three groups: preeclampsia, PAS, and a comparison group without preeclampsia or PAS. Serum levels of sFlt-1 and PlGF were determined by electrochemiluminescence immunoassay (ECL), and the ratio sFlt-1/PlGF was calculated. The optimum cutoff values were determined by the receiver operating characteristic curve, and the diagnostic performance was evaluated.
resultsOf the 200 participants, 57 (28.5%) had preeclampsia, 16 (8.0%) had PAS, and 127 (63.5%) had neither condition. At a cutoff of 77.65, the sFlt-1/PlGF ratio performed the best, with an area under the curve of 0.902 for preeclampsia, an accuracy of 88.0%, a positive predictive value (PPV) of 80.7%, a negative predictive value (NPV) of 91.3%, and a sensitivity of 80.7%. PAS had a high NPV of 97.1%, a low PPV of 18.7%, a high sensitivity of 87.5%, a low specificity of 52.0%, an accuracy of 55.9%, and an area under the curve (AUC) of 0.678.
conclusionsThe sFlt-1/PlGF ratio was an excellent discriminator of preeclampsia and could be used to help identify and stratify at-risk individuals. It is not very specific and has a low PPV in PAS, meaning that it should not be used as a surrogate for imaging-based diagnosis and clinical risk assessment in PAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.